Biohaven Pharmaceutical Holding Company Ltd banner

Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN

Watchlist Manager
Biohaven Pharmaceutical Holding Company Ltd Logo
Biohaven Pharmaceutical Holding Company Ltd
NYSE:BHVN
Watchlist
Price: 8.93 USD -0.33% Market Closed
Market Cap: $1.2B

Wall Street
Price Targets

BHVN Price Targets Summary
Biohaven Pharmaceutical Holding Company Ltd

Wall Street analysts forecast BHVN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BHVN is 21.36 USD with a low forecast of 9.09 USD and a high forecast of 52.5 USD.

Lowest
Price Target
9.09 USD
2% Upside
Average
Price Target
21.36 USD
139% Upside
Highest
Price Target
52.5 USD
488% Upside
Biohaven Pharmaceutical Holding Company Ltd Competitors:
Price Targets
WLFC
Willis Lease Finance Corp
-4% Downside
ACAD
ACADIA Pharmaceuticals Inc
55% Upside
PTGX
Protagonist Therapeutics Inc
4% Upside
NYXH
Nyxoah SA
259% Upside

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-36%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-36%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BHVN's stock price target?
Price Target
21.36 USD

According to Wall Street analysts, the average 1-year price target for BHVN is 21.36 USD with a low forecast of 9.09 USD and a high forecast of 52.5 USD.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett